GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Z

Zhuhai Rundu Pharmaceutical Co 002923.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

9.15

-1.51%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Zhuhai Rundu Pharmaceutical Co

Its shares trade on Shenzhen under the ticker 002923.SZ. It has been listed since 5 January 2018. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.18bn and a net loss of CN¥63.5m. At that date it held total assets of CN¥2.03bn and shareholders' equity of CN¥1.04bn.

Zhuhai Rundu Pharmaceutical Co., Ltd. engages in the manufacture, research and development, and marketing of pharmaceutical drugs. The company is headquartered in Zhuhai, Guangdong. The company went IPO on 2018-01-05. The Company’s products cover the fields of cardio-cerebral blood vessels, digestion and anesthesia, among others.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
5 Jan 2018
Employees
1,891
Website
rdpharma.cn ↗

Leadership

Pay as last reported

  • Mr. Xinmin ChenChairman of the Board, since 2018CN¥747,800
  • Mr. Shenhua ShiFinance Director, Deputy General ManagerCN¥591,100
  • Mr. Jie LiuGeneral Manager, Director, since 2018CN¥707,900
  • Ms. Chunyan YouDeputy General Manager, Director, since 2018CN¥656,500
  • Mr. Qiang CaiDeputy General ManagerCN¥8,900
  • Mr. Wei ChenDeputy General Manager
  • Mr. Jun SuSecretary of the Board
  • Mr. Liaoran 'Director
  • Mr. Zhengxi HuIndependent Director
  • Mr. Bo WangIndependent Director
  • Mr. Jianmu YeIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Zhuhai Rundu Pharmaceutical employs 1,891 full-time employees for research and development.
  • The company focuses on cardio-cerebral blood vessels and digestion pharmaceuticals.
  • Zhuhai Rundu Pharmaceutical has a strong presence in the Chinese pharmaceutical market.

Weaknesses

  • The company's products are limited to cardio-cerebral blood vessels and digestion fields.
  • Zhuhai Rundu Pharmaceutical has no international market presence yet.
  • The company's IPO was in 2018, indicating a relatively young market position.

Opportunities

  • Expanding into anesthesia pharmaceuticals could increase market share.
  • Growing demand for cardiovascular drugs in China presents opportunities.
  • The Chinese pharmaceutical market continues to expand rapidly.

Threats

  • Competition from established Chinese pharmaceutical companies is intense.
  • Regulatory changes in the Chinese healthcare sector could impact operations.
  • Economic downturns may reduce healthcare spending in China.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.